CAS: 1253-28-7; Gestonorone Caproate
该化合物是一种主要用于荷尔蒙疗法和避孕药物的合成蛋白质,是雌激素的酯,是天然激素蛋白质的衍生物,其特征是能够与蛋白素受体结合,从而模仿体内蛋白素的影响.Gestonorone aproate通常通过肌肉内注射进行,允许持续释放和长期行动.其药理特性包括调节月经周期,预防卵巢和孕期.该物质以其相对低温和诱发性活动而闻名,与其他蛋白质相比,适合各种治疗性应用,降低风险和诱发性副作用.此外,重要的是要考虑其在临床环境中使用的安全特征,潜在副作用和抗药性.
- 英文名称Gestonorone Caproate
- 中文名称己酸各司孕甾醇
- IUPAC名称[(8R,9S,10R,13S,14S,17R)-17-acetyl-13-methyl-3-oxo-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-yl] hexanoate
- 其它别名19-Norpregn-4-ene-3,20-dione,17-hydroxy-, hexanoate (6CI,7CI,8CI); Hexanoic acid, ester with17-hydroxy-19-norpregn-4-ene-3,20-dione (8CI); 17-Hydroxy-19-norpregn-4-ene-3,20-dione hexanoate; 17a-Hydroxy-19-norprogesteronecaproate; 17a-Hydroxy-19-norprogesteronecapronate; 17b-Acetyl-17-hydroxyestr-4-ene-3-onehexanoate; 19-Nor-17a-caproyloxy-4-pregnene-3,20-dione; 19-Norpregn-4-ene-3,20-dione17-caproate; Depostat; Gestonorone caproate; Gestonorone capronate; Gestronolcaproate; Gestronol hexanoate; Primostat
- CAS编号1253-28-7
- MFCD编号:MFCD00867860
- EINECS号:215-010-2
- FDA UNII编号:U38E620NS6
- 分子式:C26H38O4分子量:414.58
- 产品CID: 376690
- 产品分类原料药 → 激素及调节内分泌功能类药 → 雌激素及孕激素类药
物理性质
MSDS等安全信息
上下游产品
CAS号2051-49-2 正已酸酐 | CAS号2137-18-0 孕诺酮合成工艺路线路线简述
📜己酸酐,孕诺酮置于对甲苯磺酸体系中,化学反应生成己酸各司孕甾醇
参考文献:De1074582
标题:De1074582
海关参考信息
- 2901210000-乙烯
2901220000-丙烯
2905122000-异丙醇
2905143000-叔丁醇 - 💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
- 详情请参考：📖 海关编码查询和海关进出口税则
专利信息
专利号:US-9562067-B2
优先权日:2013-12-16
标题:Process for the production of 19-norpregn-4-en-3,20-dione-17α-ol(gestonorone) and intermediates therefor
发明人：Csörgei János; HORVÃ?TH ANITA; SÃ?NTA CSABA; Mahó Sándor; BÉNI ZOLTÃ?N; Horváth János
权利人:RICHTER GEDEON NYRT
摘要:The present invention relates to a new stereoselective process for the synthesis of 17(α)-17-acetyl-17-hydroxy-estr-4-en-3-one of formula (I), as well as to the new intermediates of the process. The 17(α)-17-acetyl-17-hydroxy-estr-4-en-3-one (gestonorone) is an important intermediate in the synthesis of the active ingredients having progestogen activity—such as gestonorone capronate and nomegestroi acetate. Formulas (I), (II) and (III).
专利号:BR-112016013759-B1
优先权日:2013-12-16
标 题:PROCESS FOR SYNTHESIS OF A COMPOUND, AND, COMPOUND
专利号:BR-112016013759-A2
优先权日:2013-12-16
标 题 :PROCESS FOR THE SYNTHESIS OF A COMPOUND AND COMPOUND
专利号:US-2014315720-A1
优先权日:2012-10-24
标 题 :Polysaccharide ester microspheres and methods and articles relating thereto
发明人：FALLON DENIS G; GARRETT THOMAS S; KIZER LAWTON E; ZAZZARA KAREN L; COMBS MICHAEL T; JOHNSON RICHARD K; DEHART GARY
权利人:CELANESE ACETATE LLC
摘要:A method for producing a polysaccharide ester microsphere may include forming a polysaccharide ester product from a polysaccharide synthesis, wherein the polysaccharide ester product comprises a polysaccharide ester and a solvent; diluting the polysaccharide ester product, thereby yielding a polysaccharide ester dope; and forming a plurality of polysaccharide ester microspheres from the polysaccharide ester dope. Suitable polysaccharides may include, but are not limited to, starch, cellulose, hemicellulose, algenates, chitosan, and any combination thereof. Esters thereof may be organic esters (e.g., acetate and the like), inorganic esters (e.g., sulfonates and the like), or combinations thereof. Further, the solids conent of the polysaccharide ester dope, in some instances, may be greater than about 16 wt %.
供应商参考报价(招募中)
品牌试剂参考报价(招募中)
📌 第三方产品分析报告
主要参考文献
1: Marberger M Jr, Altwein JE, Orestano F. The influence of the progestogen gestonorone caproate on testosterone turnover in renal cell carcinoma. An in vitro study. Invest Urol. 1976 Jan;13(4):302-6.
合成参考文献
摘要:S109 | PARCEDC | List of 7074 potential endocrine disrupting compounds (EDCs) by PARC T4.2 | DOI:10.5281/zenodo.10944198
参考文献:10.1159/000282559
摘要:Altwein JE, Almer F. Is there a change in the treatment of benign prostatic hyperplasia Urol Int. 1994;52(1):1–3. doi: 10.1159/000282559.
摘要:Iguchi H, Ikeuchi T, Kai Y, Yoshida H. [Influence of anti-androgen therapy for prostatic hypertrophy on lipid metabolism]. Hinyokika Kiyo. 1994 Mar;40(3):215–9.
摘要:Di Silverio F, D'Eramo G, Flammia GP, Buscarini M, Frascaro E, Mariani M, Sciarra A. [Pharmacological combinations in the treatment of benign prostatic hypertrophy]. J Urol (Paris). 1993;99(6):316–20.
📝 需求与反馈
尽可能描述清楚需求与问题信息
